NCT03893097View on ClinicalTrials.gov

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

PHASE3CompletedINTERVENTIONAL
Enrollment

726

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

March 4, 2021

Study Completion Date

March 4, 2021

Conditions
Schistosoma HaematobiumSchistosoma Mansoni
Interventions
DRUG

Praziquantel

40 mg/kg at baseline

DRUG

Artesunate + Mefloquine

4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12

Trial Locations (1)

Unknown

Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation (IRESSEF), Dakar

All Listed Sponsors
collaborator

Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation (IRESSEF)

UNKNOWN

lead

Institute of Tropical Medicine, Belgium

OTHER

NCT03893097 - Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children | Biotech Hunter | Biotech Hunter